Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANDoRA: Durvalumab and Chemo +/- Radiation in TNBC
NCT03872505Phase 2Withdrawn
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Jul 2022
- Primary completion
- Jul 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab in triple-negative breast cancer (TNBC) (2 arms), sponsored by Cedars-Sinai Medical Center. Primary endpoint: Pathological complete response rate in the breast and axilla at 20 weeks. Planned start Jul 2022; status: withdrawn.
02
Drugs
durvalumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03872505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03872505.